Kidney transplant recipients (KTRs) have experienced severe symptoms and poor outcomes with COVID-19. Because the long-term antirejection immunosuppressive drugs that KTRs take could inhibit the development of protective anti-COVID-19 immunity, most hospitals have reduced the drugs’ doses in KTRs with COVID-19. Surprisingly, reported rates of acute rejection have been low despite reduced immunosuppression in these patients. A new study in JASN provides a potential explanation.
To study KTRs’ immune responses in the face of COVID-19, a team lead by Madhav C. Menon, MBBS, crestor foamy urine MD (Yale University School of Medicine and Icahn School of Medicine at Mount Sinai) analyzed the blood of 64 KTRs with COVID-19, including 31 acute cases (< 4 weeks from diagnosis) and 33 post-acute cases (>4 weeks). Patients were enrolled form Mount Sinai and Montefiore hospital (Albert Einstein College of Medicine)—two hospitals at the forefront of the pandemic in its early months.
In the blood of acute cases, certain genes were over-expressed and others were under-expressed with higher COVID-19 severity. Analyses revealed increased expression of genes involved in innate immune pathways, but decreased expression of genes involved in the activation of adaptive immune pathways.
Comparison with post-acute cases showed “normalization” of these pathways after >4 weeks, suggesting recovery of adaptive immune system activation.
The findings of immune-insufficiency during acute COVID-19 provide an explanation for the low rates of acute rejection in KTRs despite reduced immunosuppression.
“We found that KTRs with COVID-19 showed signatures of immune-insufficiency in their peripheral blood that was even worse with severe illness—for instance among patients in the intensive care unit. We also noted that there were signals of recovery in the post-acute cases pointing to a temporary phenomenon during acute illness,” said Dr. Menon. “As this pandemic continues to affect KTRs, our collaborative findings will provide insights to the transplant community to manage anti-rejection medicines during acute COVID-19.”
Source: Read Full Article